MOTS-C vs Semaglutide for blood sugar
Short answer: For blood sugar, more users report improvement with Semaglutide — 88% of 8 reports, versus 40% of 5 for MOTS-C.
MOTS-C has 0 meta-analyses and 4 randomized trials on PubMed; Semaglutide has 421 and 307.
Based on 203 reports about MOTS-C and 314 about Semaglutide. Not medical advice.
| MOTS-C Peptide | Semaglutide Medication | |
|---|---|---|
| User score | 50 | 64 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 49% | 64% |
| Reports | 203 | 314 |
| Research | CResearch: Limited | AResearch: Strong |
| Meta-analyses / RCTs | 0 / 4 | 421 / 307 |
| Mainly used for | ||
| Weight loss % reporting improvement | 85% (13) | 84% (129) |
| Appetite % reporting improvement | — | 83% (64) |
| Focus % reporting improvement | 83% (6) | 60% (5) |
| Energy % reporting improvement | 84% (74) | 39% (23) |
| Sleep % reporting improvement | 0% (5) | 50% (4) |
| Mood % reporting improvement | 100% (5) | 27% (11) |
| Performance % reporting improvement | 85% (34) | 83% (6) |
| Recovery % reporting improvement | — | 100% (2) |
| Pain & inflammation % reporting improvement | — | 80% (5) |
| Digestion % reporting improvement | — | 43% (7) |
| Libido % reporting improvement | — | 0% (3) |
| Hormones % reporting improvement | — | 100% (2) |
| Blood sugar % reporting improvement | 40% (5) | 88% (8) |
| Heart & lipids % reporting improvement | — | 100% (3) |
| Skin & hair % reporting improvement | — | 33% (3) |
| Immunity % reporting improvement | 50% (2) | — |
| Common side effects | fatigue, insomnia, injection site, dizziness | nausea, fatigue, stomach issues, constipation |
| Typical dose reported | Not listed | 2.4 mg / once weekly |
MOTS-CFull MOTS-C profile →
What a user said
“Taking these makes me feel wildly energetic all day—zero afternoon slumps, and my endurance during cardio feels bottomless.”
SemaglutideFull Semaglutide profile →
Latest review conclusion
This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
Pharmacol Res, 2021 ↗What a user said
“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate